Novartis India reports strong half-year financial performance, profit up

Novartis India Limited's board of directors approved the unaudited financial results for the quarter and half-year ended September 30, 2025. The company reported a profit before tax of INR 698.7 million for the six months ended September 30, 2025, an increase from INR 612.4 million in the prior year. Revenue from operations reached INR 1,778.8 million for the same six-month period.

The company's total comprehensive income for the half-year stood at INR 518.4 million. Earnings per share (basic & diluted) for the six months ended September 30, 2025, were INR 21.00. Total assets as of September 30, 2025, were INR 9,318.3 million, with total equity amounting to INR 7,750.7 million.

A limited review report from BSR & Co. LLP confirmed that the financial statements were prepared in accordance with Indian Accounting Standards and SEBI regulations, with no material misstatements identified. Related party transactions for the period totaled INR 577.76 million, predominantly including royalty expenses of INR 12.87 million to Novartis AG and significant purchase of goods or services from Novartis Pharma AG and Novartis Healthcare Private Limited.